SCHEMBL3134809

SCHEMBL3134809

CC(C)(C)c1ccc(-c2cccc(S)c2-c2ccc(C(C)(C)C)cc2)cc1.O=S(=O)(O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 2/20 0.40
MMP9 P14780 2/20 0.40
MEN1 O00255 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.39
HTT P42858 1/20 0.39
KMT2A Q03164 1/20 0.39
EEF2K O00418 1/20 0.39
KIF11 P52732 2/20 0.38
HSD11B1 P28845 2/20 0.38
TRPV1 Q8NER1 1/20 0.37
MMP1 P03956 1/20 0.37
MMP3 P08254 1/20 0.37
MMP7 P09237 1/20 0.37
MMP13 P45452 1/20 0.37
PGAM1 P18669 1/20 0.36
PTGS2 P35354 2/20 0.36
NR1H4 Q96RI1 1/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3139786 0.94 MEN1 (0.43) MMP2MMP9MEN1LMNAMAPT
SCHEMBL3143584 0.90 ALDH1A1 (0.42) MMP2MMP9MEN1LMNAMAPT
SCHEMBL3140909 0.90 LMNA (0.42) MMP2MMP9LMNAMAPTHTT
SCHEMBL3132925 0.90 ALDH1A1 (0.42) MMP2MMP9MEN1LMNAMAPT
SCHEMBL3132857 0.89 KIF11 (0.44) MMP2MMP9MEN1LMNAMAPT
SCHEMBL3130395 0.89 HSD11B1 (0.44) MMP2MMP9MEN1LMNAMAPT
SCHEMBL3139853 0.88 MAPT (0.44) MMP2MMP9MEN1LMNAMAPT
Trifluoromethanesulfonic Acid SCHEMBL3136711 0.87 PTPN1 (0.36) MMP2MMP9HSD11B1TRPV1PGAM1
SCHEMBL3143278 0.87 TP53 (0.47) HSD11B1PTGS2TP53
Trifluoromethanesulfonic Acid SCHEMBL3134866 0.83 MAPT (0.39) MMP2MMP9MEN1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1676835-B1 PROCESS FOR PRODUCING TRIARYLSULFONIUM SALT WAKO PURE CHEM IND LTD (JP) 2014-12-10 EP disclosed
US-7642368-B2 for use as acid generator in semiconductor manufacture; triarylsulfonium salt having a structure that only one aromatic ring of three is different, in a high yield and by-product inhibition; reacting a diaryl sulfoxide with an aryl Grignard reagent in presence of chlorotrialkylsilane and strong acid WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 2010-01-05 US disclosed
US-20070083060-A1 for use as acid generator in semiconductor manufacture; triarylsulfonium salt having a structure that only one aromatic ring of three is different, in a high yield and by-product inhibition; reacting a diaryl sulfoxide with an aryl Grignard reagent in presence of chlorotrialkylsilane and strong acid FUJIFILM WAKO PURE CHEMICAL CORPORATION (JP) 2007-04-12 US disclosed
EP-1676835-A1 PROCESS FOR PRODUCING TRIARYLSULFONIUM SALT Wako Pure Chemical Industries, Ltd. (JP) 2006-07-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070083060-A1 for use as acid generator in semiconductor manufacture; triarylsulfonium salt having a structure that only one aromatic ring of three is different, in a high yield and by-product inhibition; reacting a diaryl sulfoxide with an aryl Grignard reagent in presence of chlorotrialkylsilane and strong acid ARSA, HAO2, HAO1 MMP2 3505/4885MMP9 3809/4885MEN1 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.